Literature DB >> 20593501

Diffusion-weighted magnetic resonance imaging to predict response of hepatocellular carcinoma to chemoembolization.

Johnathan C Chung1, Neel K Naik, Robert J Lewandowski, Jie Deng, Mary F Mulcahy, Laura M Kulik, Kent T Sato, Robert K Ryu, Riad Salem, Andrew C Larson, Reed A Omary.   

Abstract

AIM: To investigate whether intra-procedural diffusion-weighted magnetic resonance imaging can predict response of hepatocellular carcinoma (HCC) during transcatheter arterial chemoembolization (TACE).
METHODS: Sixteen patients (15 male), aged 59 +/- 11 years (range: 42-81 years) underwent a total of 21 separate treatments for unresectable HCC in a hybrid magnetic resonance/interventional radiology suite. Anatomical imaging and diffusion-weighted imaging (b = 0, 500 s/mm(2)) were performed on a 1.5-T unit. Tumor enhancement and apparent diffusion coefficient (ADC, mm(2)/s) values were assessed immediately before and at 1 and 3 mo after TACE. We calculated the percent change (PC) in ADC values at all time points. We compared follow-up ADC values to baseline values using a paired t test (alpha = 0.05).
RESULTS: The intra-procedural sensitivity, specificity, and positive and negative predictive values (%) for detecting a complete or partial 1-mo tumor response using ADC PC thresholds of +/-5%, +/-10%, and +/-15% were 77, 67, 91, and 40; 54, 67, 88, and 25; and 46, 100, 100, and 30, respectively. There was no clear predictive value for the 3-mo follow-up. Compared to baseline, the immediate post-procedure and 1-mo mean ADC values both increased; the latter obtaining statistical significance (1.48 +/- 0.29 mm(2)/s vs 1.65 +/- 0.35 x 10(-3) mm(2)/s, P < 0.014).
CONCLUSION: Intra-procedural ADC changes of > 15% predicted 1-mo anatomical HCC response with the greatest accuracy, and can provide valuable feedback at the time of TACE.

Entities:  

Mesh:

Year:  2010        PMID: 20593501      PMCID: PMC2896753          DOI: 10.3748/wjg.v16.i25.3161

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  24 in total

Review 1.  Hepatocellular carcinoma: evaluation of therapeutic response to interventional procedures.

Authors:  H K Lim; J K Han
Journal:  Abdom Imaging       Date:  2002 Mar-Apr

2.  Chemoembolization of liver tumor in a rabbit model: assessment of tumor cell death with diffusion-weighted MR imaging and histologic analysis.

Authors:  J F Geschwind; D Artemov; S Abraham; D Omdal; M S Huncharek; C McGee; A Arepally; D Lambert; A C Venbrux; G B Lund
Journal:  J Vasc Interv Radiol       Date:  2000 Nov-Dec       Impact factor: 3.464

3.  Role of diffusion-weighted imaging in estimating tumor necrosis after chemoembolization of hepatocellular carcinoma.

Authors:  Ihab R Kamel; David A Bluemke; Douglas Ramsey; Mohammad Abusedera; Michael Torbenson; John Eng; Gilberto Szarf; Jean-Francois Geschwind
Journal:  AJR Am J Roentgenol       Date:  2003-09       Impact factor: 3.959

4.  Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance.

Authors:  Angelo Sangiovanni; Ersilio Del Ninno; Pierangelo Fasani; Cristina De Fazio; Guido Ronchi; Raffaella Romeo; Alberto Morabito; Roberto De Franchis; Massimo Colombo
Journal:  Gastroenterology       Date:  2004-04       Impact factor: 22.682

5.  Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging.

Authors:  Ihab R Kamel; Eleni Liapi; Diane K Reyes; Marianna Zahurak; David A Bluemke; Jean-François H Geschwind
Journal:  Radiology       Date:  2009-02       Impact factor: 11.105

Review 6.  Global cancer statistics in the year 2000.

Authors:  D M Parkin
Journal:  Lancet Oncol       Date:  2001-09       Impact factor: 41.316

7.  Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma.

Authors:  Chung-Mau Lo; Henry Ngan; Wai-Kuen Tso; Chi-Leung Liu; Chi-Ming Lam; Ronnie Tung-Ping Poon; Sheung-Tat Fan; John Wong
Journal:  Hepatology       Date:  2002-05       Impact factor: 17.425

8.  Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial.

Authors:  Josep M Llovet; Maria Isabel Real; Xavier Montaña; Ramon Planas; Susana Coll; John Aponte; Carmen Ayuso; Margarita Sala; Jordi Muchart; Ricard Solà; Joan Rodés; Jordi Bruix
Journal:  Lancet       Date:  2002-05-18       Impact factor: 79.321

9.  Reporting results of cancer treatment.

Authors:  A B Miller; B Hoogstraten; M Staquet; A Winkler
Journal:  Cancer       Date:  1981-01-01       Impact factor: 6.860

Review 10.  Hepatocellular carcinoma.

Authors:  Josep M Llovet; Andrew Burroughs; Jordi Bruix
Journal:  Lancet       Date:  2003-12-06       Impact factor: 79.321

View more
  16 in total

1.  Novel imaging biomarkers of response to transcatheter arterial chemoembolization in hepatocellular carcinoma patients.

Authors:  Sylvain Favelier; Louis Estivalet; Pierre Pottecher; Romaric Loffroy
Journal:  Chin J Cancer Res       Date:  2015-12       Impact factor: 5.087

2.  Glutathione S-transferase O2 gene rs157077 polymorphism predicts response to transarterial chemoembolization in hepatocellular carcinoma.

Authors:  Zhixin Wang; Kai Qu; Zhichao Huang; Xinsen Xu; Jingyao Zhang; Li Zhang; Sinan Liu; Hulin Chang; Ting Lin; Yamin Liu; Wenquan Niu; Chang Liu
Journal:  Tumour Biol       Date:  2015-04-03

3.  Intraprocedural 3D Quantification of Lipiodol Deposition on Cone-Beam CT Predicts Tumor Response After Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma.

Authors:  Zhijun Wang; Rongxin Chen; Rafael Duran; Yan Zhao; Gayane Yenokyan; Julius Chapiro; Rüdiger Schernthaner; Alessandro Radaelli; MingDe Lin; Jean-François Geschwind
Journal:  Cardiovasc Intervent Radiol       Date:  2015-05-23       Impact factor: 2.740

4.  Intraprocedural transcatheter intra-arterial perfusion MRI as a predictor of tumor response to chemoembolization for hepatocellular carcinoma.

Authors:  Dingxin Wang; Ron C Gaba; Brian Jin; Ahsun Riaz; Robert J Lewandowski; Robert K Ryu; Kent T Sato; Ann B Ragin; Laura M Kulik; Mary F Mulcahy; Riad Salem; Andrew C Larson; Reed A Omary
Journal:  Acad Radiol       Date:  2011-07       Impact factor: 3.173

5.  Intraprocedural C-arm dual-phase cone-beam CT: can it be used to predict short-term response to TACE with drug-eluting beads in patients with hepatocellular carcinoma?

Authors:  Romaric Loffroy; MingDe Lin; Gayane Yenokyan; Pramod P Rao; Nikhil Bhagat; Niels Noordhoek; Alessandro Radaelli; Järl Blijd; Eleni Liapi; Jean-François Geschwind
Journal:  Radiology       Date:  2012-11-09       Impact factor: 11.105

6.  C-arm dual-phase cone-beam CT: a revolutionary real-time imaging modality to assess drug-eluting beads TACE success in liver cancer patients.

Authors:  Romaric Loffroy; Sylvain Favelier; Violaine Cherblanc; Louis Estivalet
Journal:  Quant Imaging Med Surg       Date:  2013-08

Review 7.  Multiparametric MR Imaging in Abdominal Malignancies.

Authors:  Antonio Luna; Shivani Pahwa; Claudio Bonini; Lidia Alcalá-Mata; Katherine L Wright; Vikas Gulani
Journal:  Magn Reson Imaging Clin N Am       Date:  2016-02       Impact factor: 2.266

Review 8.  Diffusion MRI in early cancer therapeutic response assessment.

Authors:  C J Galbán; B A Hoff; T L Chenevert; B D Ross
Journal:  NMR Biomed       Date:  2016-01-15       Impact factor: 4.044

9.  Magnetic resonance-imaging of the effect of targeted antiangiogenic gene delivery in a melanoma tumour model.

Authors:  Walter Hundt; Silke Steinbach; Dirk Mayer; Mykhaylo Burbelko; Andreas Kiessling; Jens Figiel; Samira Guccione
Journal:  Eur Radiol       Date:  2014-11-29       Impact factor: 5.315

Review 10.  Quantitative magnetic resonance imaging for focal liver lesions: bridging the gap between research and clinical practice.

Authors:  Roberto Cannella; Riccardo Sartoris; Jules Grégory; Lorenzo Garzelli; Valérie Vilgrain; Maxime Ronot; Marco Dioguardi Burgio
Journal:  Br J Radiol       Date:  2021-05-14       Impact factor: 3.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.